What we doState-of-the-art biotechnology
centered on antibody engineering
Areas of focus
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to
human health and well-being worldwide through innovative drug discovery and
global commercialization, driven by state-of-the-art antibody technologies,
in the core therapeutic areas of oncology, nephrology,
central nervous system and immunology.
centered on antibody
Technology-driven drug discovery
The novel drug discovery of Kyowa Kirin is firmly
supported by the exquisite experience and
technologies in research, development and
manufacture of biologics, and by open
This unique style of drug discovery is
what we call technology-driven drug discovery,
on the key technologies below.
Numerous promising pharmaceutical
candidates are emerging from our
They are the result of our
never-ending efforts in honing the edge of our
technologies and deliver
innovation in medical care.
- ※Since the development of KW-3357 for preeclampsia was discontinued in Japan, the relevant information was deleted from this table.
- ※Our main progress from December 31, 2023 are as follows.
- In January 2024, we started phase Ⅰ clinical trial of KK2269 for treatment for solid tumor in the oncology field in Japan and North America.
- In January 2024, we started phase Ⅱ clinical trial of KHK4951 (generic name : tivozanib) for treatment for diabetic macular edema in the other field in Japan, North America, South Korea, and Australia.
Around the world
Seamless collaboration between regions
delivery of novel medicines
to patients around the world,
close ties to research partners.
We are open and flexible to strategic collaborations
with pharmaceuticals, biotech,
and academia partners.